We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
ANGLE
Pursuing a multi-faceted Parsortix commercial opportunityRedx Pharma
‘004 mono insufficient in BTC; H223 combo is keyHUTCHMED
Delivering commercially and strategically during FY22Redx Pharma
Recommended all share combination with JounceScancell
Modi-1 successful in first part of Phase I/II trialScancell
A leader in antibody and vaccine oncology platformsRedx Pharma
RXC007 recruitment scales up; data now Q124Redx Pharma
Key Phase II data for lead assets expected during H223HUTCHMED
Takeda licenses fruquintinib in $1.13bn ex-China dealAvacta
AVA6000 shows signs of successful tumour targetting